Symmetry Therapeutics

Creating the world’s most robust mitochondrial carrier drug platform to treat common and rare metabolic diseases.

Symmetry Therapeutics is an early stage biotech company that creates robust mitochondrial carrier drug platform to treat common and rare metabolic diseases. Metabolic diseases range from highly prevalent chronic diseases with serious health consequences to rare, fatal inborn errors of metabolism with few or no therapeutic options. They translate their scientific advances into meaningful therapeutic options for patients. Symmetry Therapeutics is a U.S.-based company that was founded in 2015 by Jon Brestoff Parker, Thomas H. Reynolds, and Milad Alucozai.